|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM9B |
Gene summary for TMEM9B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM9B | Gene ID | 56674 |
| Gene name | TMEM9 domain family member B | |
| Gene Alias | C11orf15 | |
| Cytomap | 11p15.4 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q9NQ34 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56674 | TMEM9B | GSM4909296 | Human | Breast | IDC | 4.37e-05 | -1.71e-01 | 0.1524 |
| 56674 | TMEM9B | GSM4909297 | Human | Breast | IDC | 2.89e-04 | 1.09e-02 | 0.1517 |
| 56674 | TMEM9B | GSM4909298 | Human | Breast | IDC | 3.41e-05 | 2.57e-01 | 0.1551 |
| 56674 | TMEM9B | GSM4909307 | Human | Breast | IDC | 2.18e-02 | 2.37e-01 | 0.1569 |
| 56674 | TMEM9B | GSM4909308 | Human | Breast | IDC | 7.06e-20 | 5.41e-01 | 0.158 |
| 56674 | TMEM9B | GSM4909311 | Human | Breast | IDC | 2.55e-18 | -3.14e-03 | 0.1534 |
| 56674 | TMEM9B | GSM4909312 | Human | Breast | IDC | 2.66e-14 | 3.48e-01 | 0.1552 |
| 56674 | TMEM9B | GSM4909313 | Human | Breast | IDC | 5.83e-06 | 2.16e-01 | 0.0391 |
| 56674 | TMEM9B | GSM4909319 | Human | Breast | IDC | 1.21e-19 | -9.04e-02 | 0.1563 |
| 56674 | TMEM9B | GSM4909321 | Human | Breast | IDC | 2.04e-06 | -5.54e-02 | 0.1559 |
| 56674 | TMEM9B | brca2 | Human | Breast | Precancer | 1.47e-06 | 2.31e-01 | -0.024 |
| 56674 | TMEM9B | NCCBC14 | Human | Breast | DCIS | 1.91e-04 | -9.30e-02 | 0.2021 |
| 56674 | TMEM9B | NCCBC5 | Human | Breast | DCIS | 3.10e-06 | -2.12e-01 | 0.2046 |
| 56674 | TMEM9B | P1 | Human | Breast | IDC | 4.73e-07 | -1.82e-01 | 0.1527 |
| 56674 | TMEM9B | P2 | Human | Breast | IDC | 5.17e-07 | -1.55e-01 | 0.21 |
| 56674 | TMEM9B | DCIS2 | Human | Breast | DCIS | 5.16e-53 | 2.45e-01 | 0.0085 |
| 56674 | TMEM9B | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.81e-05 | 4.44e-01 | -0.1808 |
| 56674 | TMEM9B | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.41e-08 | 5.31e-01 | -0.0811 |
| 56674 | TMEM9B | HTA11_78_2000001011 | Human | Colorectum | AD | 2.19e-05 | 4.63e-01 | -0.1088 |
| 56674 | TMEM9B | HTA11_347_2000001011 | Human | Colorectum | AD | 7.18e-32 | 8.46e-01 | -0.1954 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00072496 | Breast | Precancer | I-kappaB kinase/NF-kappaB signaling | 27/1080 | 281/18723 | 6.58e-03 | 4.53e-02 | 27 |
| GO:00431227 | Breast | IDC | regulation of I-kappaB kinase/NF-kappaB signaling | 34/1434 | 249/18723 | 7.18e-04 | 8.77e-03 | 34 |
| GO:000724914 | Breast | IDC | I-kappaB kinase/NF-kappaB signaling | 37/1434 | 281/18723 | 8.58e-04 | 9.98e-03 | 37 |
| GO:00431236 | Breast | IDC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 26/1434 | 186/18723 | 2.06e-03 | 1.95e-02 | 26 |
| GO:004312214 | Breast | DCIS | regulation of I-kappaB kinase/NF-kappaB signaling | 32/1390 | 249/18723 | 1.67e-03 | 1.66e-02 | 32 |
| GO:000724923 | Breast | DCIS | I-kappaB kinase/NF-kappaB signaling | 35/1390 | 281/18723 | 1.80e-03 | 1.74e-02 | 35 |
| GO:004312313 | Breast | DCIS | positive regulation of I-kappaB kinase/NF-kappaB signaling | 24/1390 | 186/18723 | 5.66e-03 | 4.09e-02 | 24 |
| GO:0043123 | Colorectum | AD | positive regulation of I-kappaB kinase/NF-kappaB signaling | 60/3918 | 186/18723 | 1.91e-04 | 2.56e-03 | 60 |
| GO:0043122 | Colorectum | AD | regulation of I-kappaB kinase/NF-kappaB signaling | 76/3918 | 249/18723 | 2.17e-04 | 2.85e-03 | 76 |
| GO:0007249 | Colorectum | AD | I-kappaB kinase/NF-kappaB signaling | 82/3918 | 281/18723 | 6.09e-04 | 6.40e-03 | 82 |
| GO:00431221 | Colorectum | MSS | regulation of I-kappaB kinase/NF-kappaB signaling | 71/3467 | 249/18723 | 7.12e-05 | 1.21e-03 | 71 |
| GO:00072491 | Colorectum | MSS | I-kappaB kinase/NF-kappaB signaling | 77/3467 | 281/18723 | 1.51e-04 | 2.19e-03 | 77 |
| GO:00431231 | Colorectum | MSS | positive regulation of I-kappaB kinase/NF-kappaB signaling | 55/3467 | 186/18723 | 1.60e-04 | 2.29e-03 | 55 |
| GO:00431222 | Colorectum | FAP | regulation of I-kappaB kinase/NF-kappaB signaling | 56/2622 | 249/18723 | 1.82e-04 | 2.69e-03 | 56 |
| GO:00431232 | Colorectum | FAP | positive regulation of I-kappaB kinase/NF-kappaB signaling | 42/2622 | 186/18723 | 1.01e-03 | 9.89e-03 | 42 |
| GO:00072492 | Colorectum | FAP | I-kappaB kinase/NF-kappaB signaling | 58/2622 | 281/18723 | 1.37e-03 | 1.24e-02 | 58 |
| GO:004312220 | Esophagus | HGIN | regulation of I-kappaB kinase/NF-kappaB signaling | 63/2587 | 249/18723 | 8.91e-07 | 3.61e-05 | 63 |
| GO:000724918 | Esophagus | HGIN | I-kappaB kinase/NF-kappaB signaling | 67/2587 | 281/18723 | 3.84e-06 | 1.29e-04 | 67 |
| GO:004312317 | Esophagus | HGIN | positive regulation of I-kappaB kinase/NF-kappaB signaling | 49/2587 | 186/18723 | 4.22e-06 | 1.40e-04 | 49 |
| GO:004312318 | Esophagus | ESCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 132/8552 | 186/18723 | 2.07e-12 | 8.58e-11 | 132 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM9B | SNV | Missense_Mutation | c.563N>T | p.Lys188Met | p.K188M | Q9NQ34 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AR-A0U3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| TMEM9B | SNV | Missense_Mutation | rs770760054 | c.469N>A | p.Asp157Asn | p.D157N | Q9NQ34 | protein_coding | tolerated(0.17) | benign(0.02) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TMEM9B | SNV | Missense_Mutation | rs766273395 | c.232N>T | p.Arg78Trp | p.R78W | Q9NQ34 | protein_coding | tolerated(0.07) | possibly_damaging(0.448) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM9B | SNV | Missense_Mutation | rs764636398 | c.502G>A | p.Val168Met | p.V168M | Q9NQ34 | protein_coding | tolerated(0.09) | benign(0.015) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| TMEM9B | SNV | Missense_Mutation | novel | c.158C>A | p.Ser53Tyr | p.S53Y | Q9NQ34 | protein_coding | deleterious(0) | benign(0.22) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| TMEM9B | SNV | Missense_Mutation | novel | c.379N>T | p.Pro127Ser | p.P127S | Q9NQ34 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM9B | SNV | Missense_Mutation | rs763297397 | c.395G>A | p.Arg132His | p.R132H | Q9NQ34 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM9B | SNV | Missense_Mutation | novel | c.233G>T | p.Arg78Leu | p.R78L | Q9NQ34 | protein_coding | tolerated(0.41) | benign(0.001) | TCGA-66-2795-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| TMEM9B | SNV | Missense_Mutation | c.577N>T | p.Arg193Trp | p.R193W | Q9NQ34 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CG-5723-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM9B | SNV | Missense_Mutation | rs764636398 | c.502G>A | p.Val168Met | p.V168M | Q9NQ34 | protein_coding | tolerated(0.09) | benign(0.015) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |